Navigation Links
Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma
Date:11/9/2008

SEATTLE, Nov. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Clinical Cancer Research has published in the November 1, 2008 issue the results of a study authored by Samual Jacobs et al. investigating the use of short-course CHOP-R followed by Zevalin ([90Y]-ibritumomab tiuxetan) and extended rituximab as first-line treatment in follicular non-Hodgkin's lymphoma patients. Addition of the Zevalin therapeutic regimen increased the complete responses from 40% for patients evaluated after 3 cycles of CHOP-R alone to 82% after the Zevalin regimen.

"This study adds to recently published First-line Indolent Trial (FIT) data indicating that the addition of Zevalin in patients who respond to first-line treatment of follicular non-Hodgkin's lymphoma patients may enhance the depth of response, even in patients whose induction therapy included rituximab-containing regimens," noted Jack Singer, M.D., Chief Medical Officer at Cell Therapeutics.

This trial enrolled 60 patients of which 55 patients completed all protocol therapy. Patients who had received no prior therapy with chemotherapy or monoclonal antibody received standard dose CHOP-R for 3 cycles followed by Zevalin then were treated with rituximab weekly for 4 doses. CHOP-R related toxicities included grade 3 to 4 neutropenia occurred in 23 (39%) patients and grade 3 to 4 thrombocytopenia occurred in 3 (5%) patients. The most frequent toxicity associated with Zevalin was myelosuppression. Grade 3 to 4 neutropenia occurred in 28 (51%) of patients with one incidence of febrile neutropenia requiring hospitalization. Grade 3 to 4 thrombocytopenia occurred in 44% of patients. However, all 55 patients who received Zevalin had normal white blood counts and platelet counts by after 12 weeks following administration.

Zevalin is currently approved in the United States for the treatment of patients with relapsed or refractory, low-grade or follicular B
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
2. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
3. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
4. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
7. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
8. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
9. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
10. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
11. New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/22/2015)... is pleased to announce the appointment of Dr. ... Biochemistry. Scott joins the company after previous scientific leadership positions ... course of his nearly 20 year career in therapeutics ... recognized thought leader in the biosensor field and particularly ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... new study alcoholics are prone to a kind of disability. ... study of alcohol on the health of aged people between ... persistent problem drinking were 20 per cent more likely to ... drinkers ran a 10 per cent greater risk. These were ...
... deaths of up to 98,000 Americans annually, and that medication ... US Department of Health and Human Services (HHS) will propose ... on their products in an effort to reduce the incidence ... aimed at preventing medication errors in hospitals. The idea is ...
... Holy Grail of bad smells - a product that ... researchers believe the answer to the age-old embarrassment could ... a Toot Trapper, a cushion covered in activated charcoal, ... ,The scientists from Minneapolis Veterans' Affairs Medical ...
... away small amounts of heart tissue is as safe for ... research.// The radiofrequency catheter ablation (RFCA) treatment involves threading a ... the area of the heart which is struggling with an ... burst of radiofrequency energy, similar to microwave heat, is used ...
... called triglycerides to an increased risk of stroke. The ... triglyceride levels.// More effective screening and detection of high ... factor could further reduce the stroke burdens. ... can also prevent strokes. The precise relationship between blood ...
... the latest mood-enhancing substances to be uncovered by scientists ... may have the reverse effect. The Pennsylvania-based team believe ... ability to detect the presence or absence of hormones ... ,Denise Chen, at the Monell Chemical Senses ...
Cached Medicine News:Health News:Sniff out flatulence, 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: